Aura Biosciences Q1 2022 net loss $12.8M; cash $133.3M; AU-011 pivotal trial in 2H 2022

Aura Biosciences, Inc.

2023-Q1 EPS reported -$0.44

Net loss of $12.8M in Q1 2022 compared to $5.9M in Q1 2021; cash and marketable securities $133.3M, sufficient into 2024.
R&D expenses $8.3M (up from $4.2M) and G&A $4.5M (up from $1.7M), driven by manufacturing and public company costs.
Plan to initiate pivotal trial for AU-011 in choroidal melanoma in 2H 2022; European Commission granted Orphan Drug Designation for uveal melanoma.
IND submission for choroidal metastases and Phase 1 trial in NMIBC expected in 2H 2022, with initial data in 2023.
Preclinical data at ASCO and AACR show AU-011's broad tumor targeting and combination potential with checkpoint inhibitors.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.